clov

Clover Health is a $1.34B Medicare Advantage payer at a profitability inflection. 2026 guidance crosses into first GAAP net income on +49% revenue and +46% MA member growth. Three tailwinds added in April: CMS 2027 Final Rate +2.48% (favorable revision from +0.09% advance), 2026 Stars at PPO 3.5/HMO 4.0 with PPO #1 HEDIS nationally, and Counterpart Health delivered 450%+ YoY clinician growth with 1500bps MCR differential. Long at $3.50 PT, 60/100 conviction; CFO transition (Mar 30) is the one near-term overhang but guidance was reaffirmed.

CLOV is the only small Medicare Advantage payer guiding to first-ever GAAP profit ($0-$20M NI on +49% revenue) — with a working AI clinical platform (Counterpart Health) the market still prices at zero. We are Long at $2.52 with a $3.50 12-month target.

Strip ACO REACH and CLOV's picture is clean: insurance revenue $1.37B FY24 → $1.92B FY25 (+40%), gross profit $356M, first-ever full-year Adj EBITDA profitability ($22M) and Adj NI ($20M). 2026 guidance points to first GAAP profitability ($0-$20M NI) on $2.81B-$2.92B revenue. Balance sheet debt-free; watch item is consolidated cash and OCF, not solvency.

At $2.52 the equity is $1.34B market cap and ~$1.02B EV (after $320M consolidated cash and investments). The right lens is forward EV/Adj EBITDA and forward P/Sales — GAAP earnings near zero in 2026E make trailing P/E uninformative. On the 2026 guide midpoint ($2.86B revenue, $60M Adj EBITDA), CLOV is 0.46x forward sales and ~14-20x forward EV/Adj EBITDA across the guide range. Our $3.50 target reflects multiple expansion to ~0.65-0.70x forward sales as profitability sustains; $3.25 intrinsic is the conservative anchor.

The thesis breaks from a single MLR shock (most acute), 2027 CMS rate cuts (slower but structural), or Counterpart Health commercialization failure (removes optionality leg). Cash compression is the binding constraint that converts any of those into an existential problem.

Two segments sharing infrastructure: Insurance (99%+ revenue, MA HMO/PPO) and Counterpart Health (immaterial revenue, strategic optionality from commercialized Clover Assistant). Unit story is insurance: 113,803 MA members 12/31/25 (+38% YoY), 154-158K 2026 guide avg (+46%), MLR 88-90% est, gross profit $356M, Adj EBITDA margin 1.1%. Small but compounding flywheel; Counterpart is unlevered upside on top.

CLOV competes in the $500B+ MA market as a small AI-enabled HMO/PPO operator. The frame: 'pick up share as the giants retreat.' UNH and HUM are exiting unprofitable counties in 2025-26; CLOV gained +38% YoY members (FY25) into that vacuum. Counterpart Health (SaaS spin of Clover Assistant licensed externally) is a second competitive vector the incumbents do not run directly.

Two TAM shapes. MA: ~$500B+ premium, 33M+ enrolled lives, CLOV at ~0.3% share with multi-fold member-growth runway. Counterpart: emerging healthcare-AI / CDS SaaS market at $5-10B, where Clover sells a productized version of an already-deployed platform with published outcomes. Aggregate: 'many shots on goal' - small share of a giant market plus optionality on a nascent one.

Two-sided product: MA insurance (HMO + PPO) wrapped around an AI clinical workflow (Clover Assistant), plus a SaaS layer (Counterpart Assistant) licensing the same workflow externally. One platform tuned on Clover's COPD/CHF/diabetes population - lowers internal MLR and drives external platform revenue. The Mar 19, 2026 study (18-22% fewer flu-related acute care events in COPD/CHF patients on Counterpart Assistant) is first public evidence the platform travels.

For an insurance + healthcare-tech operator, 'supply chain' is non-physical: provider network capacity, PBM contracts, IT infrastructure for Clover Assistant and Counterpart, and reinsurance absorbing catastrophic-claim risk. Dependencies are concentrated, software-driven, and cyclical with the healthcare cost environment - the right framing because medical loss ratio (MLR) is the dominant variable, and MLR is where supply-chain economics live for an MA carrier.

CLOV's 2026 catalyst path crystallized with the April 2026 CMS 2027 Final Rate Notice (+2.48%, raised from +0.09% advance) and 2026 Star Ratings (PPO 3.5 / HMO 4.0). Forward catalysts: Q1 2026 earnings May 6 (first guide proof point under interim CFO), Counterpart Health first paying contract, October 2026 CMS 2027 Star publication, 2027 AEP cycle results.

Sell-side splits cautious-Buy / Hold. 12-month consensus PT averages ~$3.23 (range $3.00-$3.70) vs $2.52 spot and Morningstar FV $2.99. Bulls cite the 2026 GAAP profitability inflection plus Counterpart optionality; bears cite tight cash, MA loss-ratio risk, and the absence of disclosed external Counterpart contracts. Our $3.50 target sits at the top of the consensus range, reflecting conviction that 2026 guide hits at or above midpoint and Counterpart's first external paying contract lands closer than priced.

CLOV's quarterly print sequence in FY25 reads as a clean acceleration: revenue stepped from $462M in Q1 to $497M in Q3, FY25 closed at $1.92B (+40% YoY), and Adjusted EBITDA crossed positive for the full year for the first time. Management's Feb 26, 2026 guide for 2026 — $2.81-$2.92B revenue (+49%), $50-70M Adj EBITDA, and $0-20M GAAP net income — frames a step-function inflection few small payers achieve. The trajectory is bullish; the open question is durability of the cost-of-care line as membership grows another 46%.

CLOV's signal mix is mixed-to-constructive. Insider activity is unremarkable post-recovery (typical 10b5-1 selling as the share price reclaims trend). Institutional ownership is split between standard index passives and a sticky residual retail/meme-era holder base. Short interest is structurally elevated for a SPAC-era small-cap healthcare name and creates non-trivial squeeze risk on positive Adj EBITDA proof points. Trading volume remains active, supporting liquidity but also amplifying day-to-day volatility around catalysts.

CLOV's setup — small focused MA-pure-play crossing into profitability with an AI-enabled physician platform layered on top — has clean historical analogs. The instructive ones are Alignment Healthcare and Oscar Health (small recovering payers), Humana (the scale model for what an MA-pure-play earns once profitability proves out), and Bright Health (the cautionary failure mode when MLR runs away). Tempus AI and the privately-held Innovaccer round out the AI-overlay comparable set. The lesson across all of them: the inflection from "meme/SPAC discount" to "real business multiple" requires 2-3 quarters of clean Adj profitability and Star ratings stability — then the re-rating runs.

Clover's leadership is mid-transition. CEO Andrew Toy (since Jan 2023; ex-Google Cloud / Android for Work / Divide founder) leads strategy. CFO Peter Kuipers stepped down March 30, 2026 (announced Apr 1) for unspecified reasons not related to disagreement; Clay Thornton (Clover Insurance subsidiary CFO) is Interim CFO; Joe Oldakowski (VP Finance / Controller) is principal accounting officer. 2026 guidance was reaffirmed in the same disclosure. Co-founder Vivek Garipalli serves as Executive Chairman.

CLOV's primary macro variable is CMS Medicare Advantage rate-setting. The CMS 2027 Final Rate Notice (Apr 2026) materially derisked this exposure for the next 12 months: +2.48% effective benchmark increase (raised from +0.09% advance), or ~+4.98% including risk score trends — approximately $13B aggregate MA payment increase. Other macro factors: utilization environment (post-COVID normalization), interest rates (insurance float income), labor inflation in healthcare, and 2024-25 election-cycle policy on MA generally settled.

On a factor-by-factor read, CLOV looks like a textbook profitability-turnaround small-cap with embedded healthcare-AI optionality. Quality is improving (Adj EBITDA flipped positive 2025), Value is mixed (0.46x forward P/Sales is not stretched), Momentum bottomed in Q1 2025 and is recovering, Growth is unambiguously high, and the negatives — GAAP profitability, volatility, and analyst sentiment — are exactly the factors a re-rating fixes if the 2026 guide holds. Quant funds that screen on "profitability turnaround + small-cap healthcare + AI optionality" are the natural marginal buyer.

CLOV's options market reflects what the chart tells you: this is a high-IV small-cap healthcare name with a structural retail/momo bid, where IV runs in the 60-90% band and spikes around earnings and CMS rate notices. That makes outright long calls into the May 6 print expensive. The cleaner expressions for a long thesis are covered-call writing on positions you already hold, cash-secured puts at $1.75-$2.00 if you would be a forced buyer at those strikes, and event straddles around binary catalysts. The IV is the message — the market is pricing real two-way risk into every catalyst.

SPAC-era baggage largely worked through: Hindenburg (April 2021) outlasted, restatements behind, founding team in place through turnaround. Vivek Garipalli (co-founder, Executive Chairman) and Andrew Toy (CEO since Jan 2023) anchor leadership. Clean GAAP with conventional non-GAAP adjustments (SBC, restructuring). Class share structure with founder voting rights is the principal governance feature to monitor; ATM activity continues but moderating.

P/E does not work for CLOV — GAAP earnings are still negative. The right valuation kit is forward EV / Adj EBITDA + forward P/Sales + a Sum-of-the-Parts that separates the Insurance core from the Counterpart Health optionality. On that frame, the insurance business alone is roughly fair-to-attractive at $1.34B market cap; Counterpart Health is unpriced call optionality; and the SOTP supports the locked $3.50 12-month price target with multiple-expansion upside if Counterpart begins to commercialize.

How we source the tape, verify levels, and align this report with XVARY deep-dive standards.